Sánchez Cuén Jaime Alberto, Irineo Cabrales Ana Bertha, León Sicairos Nidia Maribel, Calderón Zamora Loranda, Monroy Higuera Luis, Canizalez Román Vicente Adrián
Gastroenterologia, Hospital Regional del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Cu, México.
Gastoenterología , Hospital Regional ISSSTE Culiacán , México .
Rev Esp Enferm Dig. 2017 Nov;109(11):749-756. doi: 10.17235/reed.2017.4994/2017.
After eradication treatment for Helicobacter pylori, infection could recur due to recrudescence or re-infection. The objective of this study was to determine the recurrence of Helicobacter pylori infection and identify virulent Helicobacter pylori strains one year after eradication with standard triple therapy.
A quasi-experimental study was performed that included a patient population with digestive diseases associated with Helicobacter pylori who had received standard triple therapy. Cultures and Polymerase Chain Reaction was performed on gastric biopsies for strain identification in all patients prior to eradication treatment and those with a positive carbon 14 breath test one year after eradication treatment. Statistical analysis was performed using the student T test and Fisher's exact test, statistical significance was set at 0.05.
128 patients were studied, 51 (39.8%) were male and 77 (60.2%) were female with an average age of 54.8 years (DE 13.8). There was an annual recurrence of Helicobacter pylori infection in 12 (9.3%) patients. An annual re-infection and recrudescence occurred in 9 (7 %) and 3 (2.3%) patients respectively. The recrudescence rate for cagA was 1/30 (3.3%) patients and 2/112 (1.8%) patients for vacA. The re-infection rate for cagA was 3/30 (10%) patients and 6/112 (5.3%) patients for vacA.
The recurrence of infection in this study was higher than that recorded in developed countries with a low prevalence of H. pylori and lower than that recorded in developing countries with a higher prevalence of H. pylori. The cagA or vacA s2/m2 strains were isolated after re-infection and recrudescence.
幽门螺杆菌根除治疗后,感染可能因复发或再次感染而再次出现。本研究的目的是确定标准三联疗法根除幽门螺杆菌一年后幽门螺杆菌感染的复发情况,并鉴定毒力强的幽门螺杆菌菌株。
进行了一项准实验研究,纳入了接受标准三联疗法治疗的与幽门螺杆菌相关的消化系统疾病患者群体。在根除治疗前及根除治疗一年后碳-14呼气试验呈阳性的所有患者中,对胃活检组织进行培养和聚合酶链反应以鉴定菌株。采用学生t检验和费舍尔精确检验进行统计分析,设定统计学显著性水平为0.05。
共研究了128例患者,其中男性51例(39.8%),女性77例(60.2%),平均年龄54.8岁(标准差13.8)。12例(9.3%)患者出现幽门螺杆菌感染年复发。分别有9例(7%)和3例(2.3%)患者出现年再次感染和复发。cagA的复发率为1/30(3.3%)例患者,vacA的复发率为2/112(1.8%)例患者。cagA的再次感染率为3/30(10%)例患者,vacA的再次感染率为6/112(5.3%)例患者。
本研究中的感染复发率高于幽门螺杆菌低流行率的发达国家所记录的复发率,低于幽门螺杆菌高流行率的发展中国家所记录的复发率。再次感染和复发后分离出了cagA或vacA s2/m2菌株。